Certolizumab pegol

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Certolizumab pegol
Monoclonal antibody
Type Fab' fragment
Source Humanized (from mouse)
Target TNF alpha
Clinical data
Trade names Cimzia
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a608041
Pregnancy
category
  • US: B (No risk in non-human studies)
Routes of
administration		 Subcutaneous
Legal status
Legal status
Pharmacokinetic data
Biological half-life about 11 days
Excretion Renal (PEG only)
Identifiers
CAS Number 428863-50-7 N
ATC code L04AB05 (WHO)
ChemSpider none
UNII UMD07X179E N
KEGG D03441 YesY
ChEMBL CHEMBL1201831 N
Chemical data
Formula C2115H3252N556O673S16
Molar mass 47,750 g/mol
 NYesY (what is this?)  (verify)

Certolizumab pegol [1] (CDP870, tradename Cimzia) is a biologic medication for the treatment of Crohn's disease,[2] rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. It is a fragment of a monoclonal antibody specific to tumor necrosis factor alpha (TNF-α) and is manufactured by UCB.[3][4][5]

Approvals and indications[edit]

Crohn's Disease
On April 22, 2008, the U.S. FDA approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.[4][6][7]
Rheumatoid arthritis
On June 26, 2009, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA on October 1, 2009.[8]
Psoriatic arthritis
On September 27, 2013, the U.S. FDA approved Cimzia for the treatment of adult patients with active psoriatic arthritis.[9]

Method of action[edit]

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody.[10]

Clinical trials[edit]

Crohn's disease
Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus placebo in moderate to severe active Crohn's disease.[2][10][11][12]
Axial spondyloarthritis
In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with axial spondyloarthritis.[13]
Rheumatoid arthritis
Certolizumab appears beneficial in those with rheumatoid arthritis.[14]

Side effects[edit]

Significant side effects occur in 2% of people who take the medication.[14]

References[edit]

  1. ^ Goel, Niti; Sue Stephens (2010). "Certolizumab pegol". MAbs. 2 (2): 137–147. doi:10.4161/mabs.2.2.11271. PMC 2840232Freely accessible. PMID 20190560. 
  2. ^ a b Sandborn WJ, Feagan BG, Stoinov S, et al. (July 2007). "Certolizumab pegol for the treatment of Crohn's disease". N. Engl. J. Med. 357 (3): 228–38. doi:10.1056/NEJMoa067594. PMID 17634458. 
  3. ^ Kaushik VV, Moots RJ (April 2005). "CDP-870 (certolizumab) in rheumatoid arthritis". Expert opinion on biological therapy. 5 (4): 601–6. doi:10.1517/14712598.5.4.601. PMID 15934837. 
  4. ^ a b index.cfm?fuseaction=Search.Label_ApprovalHistory "Cimzia Label and Approval History" Check |url= value (help). Drugs@FDA. U.S. Food and Drug Administration (FDA). Retrieved 2009-11-15. 
  5. ^ "Cimzia Prescribing Information" (PDF). US Food and Drug Administration (FDA). April 2016. Retrieved 2016-08-21. 
  6. ^ UCB press release - Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease. Retrieved April 22, 2008.
  7. ^ Waknine, Yael (May 1, 2008). "FDA Approvals: Patanase, Actonel, Cimzia". Medscape. Retrieved 2008-05-01. 
  8. ^ "Cimzia European Public Assessment Report". European Medicines Agency. Retrieved November 15, 2009. 
  9. ^ "Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis". Retrieved October 1, 2013. 
  10. ^ a b Schreiber S. et al.,Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise),Gut,2005,54,suppl7,A82
  11. ^ Sandborn et al., Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1),Gastroenterology, 2006,130,A107
  12. ^ "New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease" (Press release). UCB. October 23, 2006. Retrieved 2009-11-15. 
  13. ^ Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R (May 2013). "PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study". Value in Health. 16 (3): A227. doi:10.1016/j.jval.2013.03.1150. Retrieved 2013-05-18. 
  14. ^ a b Ruiz Garcia, V; Jobanputra, P; Burls, A; Cabello, JB; Vela Casasempere, P; Bort-Marti, S; Kynaston-Pearson, FJ (Sep 18, 2014). "Certolizumab pegol (CDP870) for rheumatoid arthritis in adults.". The Cochrane database of systematic reviews. 9: CD007649. doi:10.1002/14651858.CD007649.pub3. PMID 25231904. 

External links[edit]

Retrieved from "https://en.wikipedia.org/w/index.php?title=Certolizumab_pegol&oldid=749197724"